September 5, 2008 / 6:20 AM / 11 years ago

Elan, Biogen launch Tysabri trial in oncology

DUBLIN, Sept 5 (Reuters) - Biogen Idec (BIIB.O) and Elan Corp ELN.I have launched the first clinical trial of their multiple sclerosis drug Tysabri for patients with relapsed or refractory multiple myeloma, the companies said on Friday.

The first dose was administered on Thursday, they said.

Multiple myeloma is a cancer of the plasma cell. (Reporting by Jonathan Saul; Editing by Quentin Bryar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below